Equities analysts expect that Cryoport, Inc. (NASDAQ:CYRX) will announce $57.87 million in sales for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Cryoport’s earnings. The highest sales estimate is $59.99 million and the lowest is $55.60 million. Cryoport reported sales of $48.36 million in the same quarter last year, which indicates a positive year-over-year growth rate of 19.7%. The company is expected to announce its next quarterly earnings results on Monday, March 7th.
On average, analysts expect that Cryoport will report full-year sales of $224.08 million for the current financial year, with estimates ranging from $221.80 million to $226.16 million. For the next year, analysts anticipate that the business will post sales of $268.47 million, with estimates ranging from $261.50 million to $278.30 million. Zacks’ sales averages are an average based on a survey of analysts that follow Cryoport.
Cryoport (NASDAQ:CYRX) last released its earnings results on Thursday, November 4th. The consumer goods maker reported ($0.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.03). The firm had revenue of $56.69 million during the quarter, compared to the consensus estimate of $54.44 million. Cryoport had a positive return on equity of 2.67% and a negative net margin of 12.57%. Cryoport’s revenue was up 407.5% compared to the same quarter last year. During the same quarter last year, the business posted ($0.29) EPS.
NASDAQ CYRX traded down $0.28 during trading on Friday, hitting $45.50. The stock had a trading volume of 421,146 shares, compared to its average volume of 622,255. Cryoport has a one year low of $43.51 and a one year high of $86.30. The stock has a 50 day simple moving average of $62.79 and a 200 day simple moving average of $64.20. The stock has a market capitalization of $2.11 billion, a price-to-earnings ratio of -25.42 and a beta of 0.88. The company has a debt-to-equity ratio of 0.18, a quick ratio of 9.66 and a current ratio of 9.99.
In other news, CEO Jerrell Shelton sold 65,250 shares of the business’s stock in a transaction on Wednesday, November 10th. The stock was sold at an average price of $79.23, for a total value of $5,169,757.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Daniel M. Hancock sold 11,217 shares of the company’s stock in a transaction on Thursday, October 21st. The stock was sold at an average price of $75.74, for a total value of $849,575.58. The disclosure for this sale can be found here. In the last 90 days, insiders sold 641,717 shares of company stock valued at $48,270,373. Company insiders own 10.90% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Captrust Financial Advisors boosted its position in shares of Cryoport by 35.4% in the 3rd quarter. Captrust Financial Advisors now owns 624 shares of the consumer goods maker’s stock worth $42,000 after purchasing an additional 163 shares in the last quarter. Pinnacle Bancorp Inc. purchased a new stake in shares of Cryoport during the third quarter worth about $59,000. FinTrust Capital Advisors LLC increased its holdings in shares of Cryoport by 199.6% during the second quarter. FinTrust Capital Advisors LLC now owns 1,504 shares of the consumer goods maker’s stock valued at $95,000 after acquiring an additional 1,002 shares in the last quarter. Nisa Investment Advisors LLC raised its position in shares of Cryoport by 500.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,400 shares of the consumer goods maker’s stock valued at $151,000 after purchasing an additional 2,000 shares during the last quarter. Finally, Dark Forest Capital Management LP acquired a new stake in Cryoport in the 2nd quarter worth approximately $157,000.
Cryoport Company Profile
CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.
Recommended Story: Book Value Of Equity Per Share – BVPS Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cryoport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryoport and related companies with MarketBeat.com's FREE daily email newsletter.